China: Researchers have found in a new meta-analysis that mepolizumab is an effective and safe treatment for severe ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...

Among patients with asthma-like symptoms in primary care, testing using home spirometry may be useful for the diagnosis of ...

Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

OPEN The FTSE 100 was expected to open 57 points higher (+0.6%) ahead of the bell on Monday, after finishing Friday's session 0.2% higher at a record closing price of 9,951.14.

GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils.

Objectives In patients with chronic obstructive pulmonary disease (COPD), severe exacerbations (ECOPDs) impose significant morbidity and mortality. Current guidelines emphasise using ECOPD history to ...

Robin has worked as a credit cards, editor and spokesperson for over a decade. Prior to Forbes Advisor, she also covered credit cards and related content for other national web publications including ...

Unless you're taking advantage of an intro 0% APR offer, if you carry a balance on your credit card, you're likely being hit with high interest charges. The average APR for all credit card accounts is ...